August 29, 2024 09:35 AM EDT
News Briefing

J&J heads to FDA for Vyv­gart com­peti­tor; Tokyo con­glom­er­ate launch­es ven­ture fund

ENDPOINTS

John­son & John­son sub­mits FDA ap­pli­ca­tion for Vyv­gart com­peti­tor: The phar­ma com­pa­ny is seek­ing ap­proval of nipocal­imab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times